The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.
Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.
Analysts following Diamyd Medical: Johan Lochen, Erik Penser Bank. Phone: +46 8 463 80 00. Erik Penser Bank equity research
Felicia Rittemar, Vator Securities, Phone: +46 8 5333 2737. Vator Securities equity research
Up to half of all patients diagnosed with type 1 diabetes carry the diabetes susceptibility genes HLA DR3-DQ2. These individuals have a high likelihood of responding to Diamyd® treatment. Last month’s publication of the peer-reviewed article highlighting the topline clinical and immunological findings from DIAGNODE-2 in the leading diabetes journal Diabetes Care, has significantly increased the awareness and visibility for the novel precision medicine approach we are pursuing and has so far...
The findings and the publication in Diabetes Care strongly support the diabetes vaccines’s efficacy in preserving beta cell function in individuals carrying the DR3-DQ2 genes. Ulf Hannelius, President and CEO